| langue originale | Anglais |
|---|---|
| Pages (de - à) | e12-e13 |
| journal | European Urology |
| Volume | 79 |
| Numéro de publication | 1 |
| Les DOIs | |
| état | Publié - 1 janv. 2021 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
McHenry, M. B., Drake, C. G., & Fizazi, K. (2021). Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer. European Urology, 79(1), e12-e13. https://doi.org/10.1016/j.eururo.2020.10.012
McHenry, M. Brent ; Drake, Charles G. ; Fizazi, Karim. / Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re : Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer. Dans: European Urology. 2021 ; Vol 79, Numéro 1. p. e12-e13.
@article{19e246e468f44d3ca25edac1e1e0548e,
title = "Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer",
author = "McHenry, {M. Brent} and Drake, {Charles G.} and Karim Fizazi",
year = "2021",
month = jan,
day = "1",
doi = "10.1016/j.eururo.2020.10.012",
language = "English",
volume = "79",
pages = "e12--e13",
journal = "European Urology",
issn = "0302-2838",
number = "1",
}
McHenry, MB, Drake, CG & Fizazi, K 2021, 'Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer', European Urology, VOL. 79, Numéro 1, p. e12-e13. https://doi.org/10.1016/j.eururo.2020.10.012
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer. / McHenry, M. Brent; Drake, Charles G.; Fizazi, Karim.
Dans: European Urology, Vol 79, Numéro 1, 01.01.2021, p. e12-e13.
Dans: European Urology, Vol 79, Numéro 1, 01.01.2021, p. e12-e13.
Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs
TY - JOUR
T1 - Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re
T2 - Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer
AU - McHenry, M. Brent
AU - Drake, Charles G.
AU - Fizazi, Karim
PY - 2021/1/1
Y1 - 2021/1/1
UR - http://www.scopus.com/inward/record.url?scp=85095985446&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2020.10.012
DO - 10.1016/j.eururo.2020.10.012
M3 - Letter
C2 - 33121826
AN - SCOPUS:85095985446
SN - 0302-2838
VL - 79
SP - e12-e13
JO - European Urology
JF - European Urology
IS - 1
ER -
McHenry MB, Drake CG, Fizazi K. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer. European Urology. 2021 janv. 1;79(1):e12-e13. doi: 10.1016/j.eururo.2020.10.012